Everence Capital Management Inc. Sells 1,390 Shares of Moderna, Inc. (NASDAQ:MRNA)

Everence Capital Management Inc. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 14.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 7,940 shares of the company’s stock after selling 1,390 shares during the period. Everence Capital Management Inc.’s holdings in Moderna were worth $330,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna during the 2nd quarter valued at about $26,000. Plato Investment Management Ltd grew its stake in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of Moderna by 1,753.1% in the 2nd quarter. Larson Financial Group LLC now owns 593 shares of the company’s stock worth $70,000 after buying an additional 561 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Moderna in the second quarter valued at $75,000. Finally, Blue Trust Inc. raised its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on MRNA shares. The Goldman Sachs Group reduced their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Bank of America reissued an “underperform” rating and set a $41.00 price target on shares of Moderna in a research note on Tuesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Berenberg Bank started coverage on shares of Moderna in a research report on Tuesday, November 19th. They issued a “hold” rating and a $42.00 target price on the stock. Finally, Wolfe Research began coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Four research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $79.50.

Moderna Stock Performance

NASDAQ:MRNA opened at $42.57 on Tuesday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm’s fifty day simple moving average is $43.38 and its 200 day simple moving average is $71.48. The stock has a market cap of $16.38 billion, a P/E ratio of -7.31 and a beta of 1.60. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the company earned ($1.39) earnings per share. Moderna’s quarterly revenue was up 3.8% on a year-over-year basis. As a group, research analysts predict that Moderna, Inc. will post -9.3 EPS for the current year.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.